JP2020532965A5 - - Google Patents

Download PDF

Info

Publication number
JP2020532965A5
JP2020532965A5 JP2020510103A JP2020510103A JP2020532965A5 JP 2020532965 A5 JP2020532965 A5 JP 2020532965A5 JP 2020510103 A JP2020510103 A JP 2020510103A JP 2020510103 A JP2020510103 A JP 2020510103A JP 2020532965 A5 JP2020532965 A5 JP 2020532965A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
antibody
acid sequence
hvr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020510103A
Other languages
English (en)
Japanese (ja)
Other versions
JP7369688B2 (ja
JP2020532965A (ja
Filing date
Publication date
Priority claimed from PCT/CN2017/098332 external-priority patent/WO2019036855A1/en
Application filed filed Critical
Publication of JP2020532965A publication Critical patent/JP2020532965A/ja
Publication of JP2020532965A5 publication Critical patent/JP2020532965A5/ja
Priority to JP2022189388A priority Critical patent/JP2023036590A/ja
Application granted granted Critical
Publication of JP7369688B2 publication Critical patent/JP7369688B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020510103A 2017-08-21 2018-08-21 抗cd137分子及びその使用 Active JP7369688B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022189388A JP2023036590A (ja) 2017-08-21 2022-11-28 抗cd137分子及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2017/098332 2017-08-21
PCT/CN2017/098332 WO2019036855A1 (en) 2017-08-21 2017-08-21 Anti-cd137 molecules and use thereof
PCT/CN2018/101501 WO2019037711A1 (en) 2017-08-21 2018-08-21 ANTI-CD137 MOLECULES AND CORRESPONDING USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022189388A Division JP2023036590A (ja) 2017-08-21 2022-11-28 抗cd137分子及びその使用

Publications (3)

Publication Number Publication Date
JP2020532965A JP2020532965A (ja) 2020-11-19
JP2020532965A5 true JP2020532965A5 (enExample) 2021-09-30
JP7369688B2 JP7369688B2 (ja) 2023-10-26

Family

ID=65360267

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020510103A Active JP7369688B2 (ja) 2017-08-21 2018-08-21 抗cd137分子及びその使用
JP2022189388A Pending JP2023036590A (ja) 2017-08-21 2022-11-28 抗cd137分子及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022189388A Pending JP2023036590A (ja) 2017-08-21 2022-11-28 抗cd137分子及びその使用

Country Status (12)

Country Link
US (3) US11859003B2 (enExample)
EP (1) EP3672991A4 (enExample)
JP (2) JP7369688B2 (enExample)
KR (1) KR102741435B1 (enExample)
CN (3) CN111511762B (enExample)
AU (1) AU2018320257B2 (enExample)
BR (1) BR112020003601B1 (enExample)
IL (1) IL272700B1 (enExample)
MX (1) MX2020001996A (enExample)
SG (1) SG11202001562YA (enExample)
WO (2) WO2019036855A1 (enExample)
ZA (1) ZA202001113B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017127755A1 (en) 2016-01-20 2017-07-27 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
US11096964B2 (en) * 2016-01-20 2021-08-24 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
BR112020000719A2 (pt) 2017-07-11 2020-07-14 Compass Therapeutics Llc anticorpos agonistas que ligam o cd137 humano e seus usos
KR102776166B1 (ko) 2017-08-07 2025-03-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 안전한 세포 치료제를 생성하기 위한 플랫폼
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
WO2019100052A2 (en) 2017-11-20 2019-05-23 Compass Therapeutics Llc Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
SG11202008261WA (en) 2018-03-08 2020-09-29 Rubius Therapeutics Inc Therapeutic cell systems and methods for treating cancer and infectious diseases
JP7598312B2 (ja) 2018-07-23 2024-12-11 ハイデルベルク ファーマ リサーチ ゲーエムベーハー 同種異系の細胞療法における抗-cd137抗体薬物コンジュゲート(adc)の使用
KR102697702B1 (ko) 2018-08-10 2024-08-22 추가이 세이야쿠 가부시키가이샤 항cd137 항원 결합 분자 및 그의 사용
KR20210125978A (ko) 2018-11-01 2021-10-19 그라셀 바이오테크놀로지스 (상하이) 컴퍼니, 리미티드 T 세포 조작을 위한 조성물 및 방법
WO2020112647A1 (en) 2018-11-27 2020-06-04 Khona Scientific Llc Bidirectional multi-enzymatic scaffolds for biosynthesizing cannabinoids
SG11202110287QA (en) 2019-04-24 2021-10-28 Heidelberg Pharma Res Gmbh Amatoxin antibody-drug conjugates and uses thereof
AU2020287181A1 (en) * 2019-06-05 2022-01-20 Adagene Pte. Ltd. Anti-CD137L antibodies and methods of using same
JP7432716B2 (ja) * 2019-11-13 2024-02-16 合肥瀚科邁博生物技術有限公司 ヒト4-1bbに結合可能な分子及びその応用
CN117843786A (zh) * 2019-11-19 2024-04-09 非同(成都)生物科技有限公司 人源化4-1bb单克隆抗体及其药物组合物
TWI895351B (zh) * 2020-02-12 2025-09-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
EP4103608A1 (en) * 2020-02-13 2022-12-21 UCB Biopharma SRL Bispecific antibodies against cd9 and cd137
BR112022016491A2 (pt) * 2020-02-28 2022-10-11 Shanghai Henlius Biotech Inc Construto anti-cd137 e usos do mesmo
CA3177717A1 (en) * 2020-05-13 2021-11-18 Adagene Ag Compositions and methods for treating cancer
WO2021226883A1 (en) * 2020-05-13 2021-11-18 Adagene Ag Compositions and methods for treating cancer submission of sequence listing on ascii text file
EP4153316A1 (en) 2020-05-19 2023-03-29 Boehringer Ingelheim International GmbH Binding molecules for the treatment of cancer
CA3181677A1 (en) * 2020-06-23 2021-12-30 Guizhong Liu Combination therapy comprising anti-cd137 antibodies
IL300225A (en) * 2020-07-31 2023-03-01 Chugai Pharmaceutical Co Ltd A pharmaceutical composition including chimeric receptor expressing cells
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
WO2022218264A1 (en) * 2021-04-11 2022-10-20 Adagene Inc. Combination therapies for treating cancer
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
US20240417482A1 (en) * 2021-10-12 2024-12-19 Concept To Medicine Biotech Co., Ltd. Single-domain 4-1bb antibodies
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024114676A1 (zh) 2022-11-29 2024-06-06 江苏恒瑞医药股份有限公司 Cldn18.2/4-1bb结合蛋白及其医药用途
CN121666232A (zh) 2023-05-31 2026-03-13 开普斯坦治疗公司 脂质纳米颗粒制剂和组合物
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
DK0616640T3 (da) 1991-12-02 2004-12-20 Medical Res Council Fremstilling af anti-selv antistoffer fra repertoirer af antistofsegmenter og fremvist på fag
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
US7138500B1 (en) 1993-05-07 2006-11-21 Immunex Corporation Antibodies to human 4-1BB
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
DE69624436T2 (de) * 1995-04-08 2003-08-28 Lg Chemical Ltd., Seoul/Soul Humaner 4-1bb spezifischer humaner antikörper und diesen produzierende zellinie
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル,インコーポレイテッド 免疫療法のctla−4結合ペプチド
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
KR20000034847A (ko) * 1998-11-17 2000-06-26 성재갑 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물
DK2112166T3 (en) 1998-12-23 2019-02-04 Pfizer Human monoclonal antibodies to CTLA-4
US6974684B2 (en) 2001-08-08 2005-12-13 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20030118588A1 (en) 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
DE60022369T2 (de) 1999-10-04 2006-05-18 Medicago Inc., Sainte Foy Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
JP4200627B2 (ja) 2000-03-01 2008-12-24 味の素株式会社 変異型チロシンリプレッサー遺伝子とその利用
EP2796468A2 (en) 2001-01-05 2014-10-29 Pfizer Inc Antibodies to insulin-like growth factor I receptor
CA2436326C (en) 2001-01-09 2012-08-14 Merck Patent Gesellschaft Mit Beschraenkter Haftung Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
CA2447851C (en) 2001-06-28 2012-08-28 Domantis Limited Dual-specific ligand and its use
CN1604795B (zh) 2001-08-17 2010-05-26 科勒制药股份公司 具有提高的活性的组合基序免疫刺激寡肽
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
AU2003217906A1 (en) 2002-03-01 2003-09-16 Dyax Corp. Modular recombinatorial display libraries
EP1517921B1 (en) 2002-06-28 2006-06-07 Domantis Limited Dual specific ligands with increased serum half-life
WO2004010947A2 (en) * 2002-07-30 2004-02-05 Bristol-Myers Squibb Company Humanized antibodies against human 4-1bb
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
PL216630B1 (pl) 2002-10-17 2014-04-30 Genmab As Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie
ES2347241T3 (es) 2002-12-16 2010-10-27 Genentech, Inc. Variantes de inmunoglobulina y sus utilizaciones.
EP1578801A2 (en) 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
JP4889493B2 (ja) 2003-05-14 2012-03-07 ドマンティス リミテッド ポリペプチドレパートリーから可逆的にアンフォールドするポリペプチドを回収するための方法
SI1639011T1 (sl) 2003-06-30 2009-04-30 Domantis Ltd Pegilirana protitelesa z enojno domeno (dAb)
AR046094A1 (es) * 2003-10-10 2005-11-23 Bristol Myers Squibb Co Anticuerpos completamente humanos contra 4-1bb humano
US7288638B2 (en) * 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US20070253961A1 (en) 2004-06-09 2007-11-01 Ulsan Industrial Education Foundation Pharmaceutical Composition Comprising the Anti-4-1Bb Antibody for Treating or Preventing Rheumatoid Arthritis
US20080152655A1 (en) 2004-09-08 2008-06-26 The Ohio State University Research Foundation Combination Therapy With Anti-Ctla4 and Anti-4-1BB Antibodies
WO2006055697A2 (en) 2004-11-17 2006-05-26 Board Of Regents, The University Of Texas System Cancer immunotherapy incorporating p53
DE102004063494A1 (de) 2004-12-23 2006-07-13 Tegenero Ag Antikörper
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
EP2399935A3 (en) 2005-02-15 2012-02-22 GTC Biotherapeutics, Inc. An anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
JP2008542354A (ja) 2005-06-03 2008-11-27 ファイザー・プロダクツ・インク 癌治療におけるerbB2阻害剤と他の治療薬の併用
TWI478940B (zh) 2005-08-26 2015-04-01 Roche Glycart Ag 具有經改變細胞傳訊活性之改質抗原結合分子
CN1294146C (zh) 2005-10-17 2007-01-10 山东大学 与t细胞表面共刺激分子cd137结合的多肽及其应用
AU2015201981A1 (en) * 2005-10-21 2015-05-07 Genzyme Corporation Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
WO2007062093A2 (en) 2005-11-22 2007-05-31 Incyte Corporation Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
AU2006317242A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
CL2007003291A1 (es) * 2006-11-15 2008-07-04 Medarex Inc Anticuerpo monoclonal humano aislado que enlaza la proteina btla o fragmentos del mismo; acido nucleico que lo codifica; metodo de produccion; composicion e inmunoconjugado que los comprende; y metodo para inhibir el crecimiento de celulas de tumor e
KR20080107050A (ko) 2007-06-05 2008-12-10 울산대학교 산학협력단 항-cd137 단일클론 항체를 포함하는 만성이식편대숙주 질환의 예방 또는 치료용 약학적 조성물
US7879984B2 (en) 2007-07-31 2011-02-01 Regeneron Pharmaceuticals, Inc. Human antibodies to human CD20 and method of using thereof
WO2009022215A1 (en) 2007-08-13 2009-02-19 Pfizer Inc. Combination motif immune stimulatory oligonucleotides with improved activity
CA3128656A1 (en) 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
AU2013202755B2 (en) 2007-08-22 2016-05-12 Cytomx Therapeutics, Inc. Activatable binding polypeptides and methods of identification and use thereof
ES2336873B1 (es) 2007-11-07 2011-01-24 Proyecto De Biomedicina Cima, S.L. Composicion farmaceutica para el tratamiento de cancer.
HUE032735T2 (en) 2007-12-14 2017-10-30 Bristol Myers Squibb Co Binding molecules for the human OX40 receptor
US8119129B2 (en) 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
EP3543256A1 (en) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
US20120076722A1 (en) 2009-05-14 2012-03-29 University Of Maryland, Baltimore Methods for treating cancers and diseases associated with 4-1bb (cd137) expression
US9193791B2 (en) 2010-08-03 2015-11-24 City Of Hope Development of masked therapeutic antibodies to limit off-target effects
CN103221428B (zh) 2010-09-09 2016-02-10 辉瑞公司 4-1bb结合分子
HRP20210642T1 (hr) 2010-11-12 2021-05-28 Nektar Therapeutics Konjugati il-2 ostatka i polimera
WO2013192550A2 (en) 2012-06-22 2013-12-27 Cytomx Therapeutics, Inc. Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
CN105247050B (zh) 2013-03-14 2020-06-16 天演药业 用于文库构建、亲和力结合剂筛选和其表达的整合系统
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
RU2715232C2 (ru) 2013-09-25 2020-02-26 Сайтомкс Терапьютикс, Инк. Субстраты матриксной металлопротеиназы и другие расщипляемые фрагменты и способы их использования
MX2016007885A (es) 2013-12-17 2017-01-11 Genentech Inc Metodos de tratamiento de cancer usando antagonistas de union del eje de pd-1 y un anticuerpo anti-cd20.
SG11201604965RA (en) 2013-12-20 2016-07-28 Univ Singapore Differentiation therapy with cd137 ligand agonists
US10010587B2 (en) 2014-02-21 2018-07-03 Nektar Therapeutics IL-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody
JP2017513818A (ja) * 2014-03-15 2017-06-01 ノバルティス アーゲー キメラ抗原受容体を使用する癌の処置
ES2900898T3 (es) 2014-04-07 2022-03-18 Chugai Pharmaceutical Co Ltd Anticuerpos biespecíficos inmunoactivadores
AU2015292406B2 (en) 2014-07-25 2021-03-11 Cytomx Therapeutics, Inc Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
WO2016115275A1 (en) 2015-01-13 2016-07-21 City Of Hope Ctla4-binding protein peptide-linker masks
CA2976446A1 (en) 2015-02-13 2016-08-18 Sorrento Therapeutics, Inc. Antibody therapeutics that bind ctla4
TW201632559A (zh) 2015-02-22 2016-09-16 索倫多醫療公司 結合cd137之抗體治療劑
AU2016233495B2 (en) 2015-03-13 2022-02-24 Cytomx Therapeutics, Inc Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
SG10202110908WA (en) 2015-05-04 2021-11-29 Cytomx Therapeutics Inc Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof
AU2016258988A1 (en) 2015-05-04 2017-12-07 Cytomx Therapeutics, Inc Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof
US11008396B2 (en) 2015-05-21 2021-05-18 Alligator Bioscience Ab Polypeptides
WO2016200645A1 (en) 2015-06-12 2016-12-15 Tianxin Wang Methods for protein modification in pharmaceutical applications
CN114591433A (zh) 2015-07-13 2022-06-07 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
JP6845846B6 (ja) * 2015-09-22 2021-04-21 ディンフー バイオターゲット カンパニー リミテッド 抗ヒトcd137の完全ヒト抗体及びその用途
GB201519481D0 (en) 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
US10618960B2 (en) 2015-12-15 2020-04-14 Oncoimmune, Inc. Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof
ES2986067T3 (es) 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
US20190016812A1 (en) 2015-12-22 2019-01-17 Abbvie Stemcentrx Llc Novel anti-tnfsf9 antibodies and methods of use
EP3417293A1 (en) 2016-02-18 2018-12-26 Institut Gustave Roussy Methods and kits for predicting the sensitivity of a subject to immunotherapy
KR20180132070A (ko) 2016-03-03 2018-12-11 큐 바이오파마, 인크. T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
EP3464362B1 (en) 2016-05-27 2020-12-09 AbbVie Biotherapeutics Inc. Anti-4-1bb antibodies and their uses
CA3030636A1 (en) * 2016-07-14 2018-01-18 Genmab A/S Multispecific antibodies against cd40 and cd137
CN107840887B (zh) 2016-09-21 2022-03-25 基石药业(苏州)有限公司 一种新的pd-1单克隆抗体
GB201619648D0 (en) 2016-11-21 2017-01-04 Alligator Bioscience Ab Novel antibodies and uses thereof
WO2018127787A1 (en) * 2017-01-06 2018-07-12 Eutilex Co., Ltd. Anti-human 4-1 bb antibodies and use thereof
KR102629972B1 (ko) 2017-04-13 2024-01-29 아게누스 인코포레이티드 항-cd137 항체 및 이의 사용 방법
KR20180119135A (ko) 2017-04-24 2018-11-01 주식회사 제넥신 4-1bbl 변이체 및 이를 포함하는 융합 단백질
CN110709421A (zh) 2017-05-02 2020-01-17 鳄鱼生物科学公司 针对ox40和ctla-4的双特异性抗体
JP7173993B2 (ja) 2017-05-19 2022-11-17 ウーシー バイオロジクス(シャンハイ)カンパニー リミテッド 細胞傷害性tリンパ球関連タンパク質4(ctla-4)に対する新規モノクローナル抗体
BR112020000719A2 (pt) 2017-07-11 2020-07-14 Compass Therapeutics Llc anticorpos agonistas que ligam o cd137 humano e seus usos
GB201712032D0 (en) 2017-07-26 2017-09-06 Bioinvent Int Ab Antibodies and uses thereof
CN111511762B (zh) * 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
CA3072143A1 (en) 2017-08-21 2019-02-28 Adagene Inc. Dynamic human heavy chain antibody libraries
JP7324744B2 (ja) 2017-08-21 2023-08-10 アダジーン インコーポレイテッド ダイナミックヒト抗体軽鎖ライブラリー
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
WO2019104716A1 (en) 2017-12-01 2019-06-06 Adagene Inc. Methods for using cd137 ligand as biomarker for treatment with anti-cd137 antibody
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
AU2020287181A1 (en) 2019-06-05 2022-01-20 Adagene Pte. Ltd. Anti-CD137L antibodies and methods of using same
CA3177717A1 (en) 2020-05-13 2021-11-18 Adagene Ag Compositions and methods for treating cancer
CA3181677A1 (en) 2020-06-23 2021-12-30 Guizhong Liu Combination therapy comprising anti-cd137 antibodies
WO2022170619A1 (en) 2021-02-11 2022-08-18 Adagene Pte. Ltd. Anti-cd3 antibodies and methods of use thereof
WO2023168547A1 (en) 2022-03-07 2023-09-14 Adagene Pte. Ltd. Anti-cd137 antibodies and methods of making and using the same

Similar Documents

Publication Publication Date Title
JP2020532965A5 (enExample)
CN110799539B (zh) 抗4-1bb抗体及其制备和使用方法
EP3341020B1 (en) Pd-l1 ("programmed death-ligand 1") antibodies
JP2018527919A5 (enExample)
JP2020511947A5 (enExample)
US20170015758A1 (en) Compositions And Methods For Modulating And Redirecting Immune Responses
RU2018100820A (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА И АНТИТЕЛА С СОЗРЕВШЕЙ АФФИННОСТЬЮ ПРОТИВ FcRH5 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2018503365A5 (enExample)
JP2018527952A5 (enExample)
RU2017119543A (ru) Анти-tim3 антитела и способы их применения
JP2018035138A5 (enExample)
RU2016129274A (ru) Канинизированные мышиные антитела к человеческому pd-1
JP2014158469A5 (enExample)
JP2015500207A5 (enExample)
RU2013143358A (ru) Анти-fgfr4 антитела и способы их применения
JP2018533371A5 (enExample)
RU2017118225A (ru) Антитела к PD-1 и способы их применения
JP2013520984A5 (enExample)
CN106068275A (zh) 抗pd‑1的人抗体
JPWO2019224718A5 (enExample)
JP2019530431A5 (enExample)
KR20190109574A (ko) 암 치료를 위한 항-fam19a5 항체의 용도
US20240002526A1 (en) Uses of effector cell engaging molecules with moieties of differing potencies
RU2008138541A (ru) Способы разрушения клеток с использованием эффекторных функций анти-epha4 антител
RU2013106217A (ru) Гибридный белок из антитела против мнс и противовирусного цитокина